The NOTCH1 gene displays a determinant biologic role in hematopoiesis. 3 Following the pivotal study that identified NOTCH1 mutations in CLL and provided initial evidence on the unfavorable clinical outcome associated with NOTCH1 alterations, 4 two independent studies based on the CLL coding genome have recently identified activating mutations of the NOTCH1 gene in ~10% of CLL at diagnosis. 5, 6 The prevalence of NOTCH1 mutations increases with disease aggressiveness. 5 At diagnosis, NOTCH1 mutations show an adverse impact on outcome, confirmed in at least four series, 4-7 and act independent of other clinico-biologic features, including TP53 disruption. 7 Among CLL cytogenetic subgroups, NOTCH1 mutations distribute in a mutually exclusive fashion with TP53 disruption and are enriched in CLL carrying +12, where they recur in ~25% of patients.
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Based on the emerging association between NOTCH1 alterations and +12, we investigated NOTCH1 mutations in a series of untreated +12 CLL and report that, among them, NOTCH1 mutations: i) cluster within cases devoid of additional cytogenetic abnormalities; ii) induce a peculiar transcriptional profiling; and iii) refine outcome prediction.
Patients and methods

Patients
This multicentric study evaluated 104 patients carrying +12: 54 were males and 50 females, with a median age of 65 years (interquartile range: 56-72). All cases satisfied the IWCLL diagnostic criteria for CLL 8 and were selected on the basis of: i) untreated disease; ii) availability of biologic material; and iii) presence of +12, independent of additional chromosomal abnormalities. sequencing were performed as previously described.
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Mutation analysis of NOTCH1
The NOTCH1 (exon 34; RefSeq NM_017617.2) mutation hotspot previously identified in CLL 7 was analyzed by direct sequencing of genomic DNA extracted from blood mononuclear cells. Purified amplicons were subjected to conventional DNA Sanger sequencing using the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, CA).
The presence of NOTCH1 c.7544_7545delCT alleles was also investigated by ARMS PCR. Further details are reported in Supplementary Methods.
Statistical analysis
OS was measured from the date of initial presentation to the date of death (event) or last follow-up (censoring). Survival analysis was performed by the Kaplan-Meier method. Further details are reported in Supplementary Methods.
Gene expression profile analysis
For oligonucleotide array analysis, the HGU133 Plus 2.0 gene chips (Affymetrix, Santa Clara, CA) were used. Sample preparation and microarray processing were performed as previously described. 10 Further details are reported in Supplementary Methods.
Results and Discussion
Frequency and distribution of NOTCH1 mutations in +12 CLL
NOTCH1 mutations occurred in 25 of the 104 untreated CLL with +12 investigated (24%) (Table 1a) , were represented in all cases by frameshift deletions, including the c.7544_7545delCT in 22/25 (88%) cases, and preferentially associated with usage of unmutated IGHV genes (84%, p=.003). NOTCH1 mutations occurred independent of gender, thus suggesting that NOTCH1 mutations might be an important marker of unfavorable prognosis in both male and female CLL patients.
Trisomy 12 occurred as an isolated chromosomal abnormality in 73/104 (70%) cases, whilst associated to other cytogenetic abnormalities in 31/104 (30%) cases ( Figure 1A ).
Mutual information analysis revealed a clustering of NOTCH1 mutations among CLL harboring +12 as a sole abnormality (22/73, 30%) compared to patients harboring +12 in addition to other cytogenetic lesions (2/31, 6%) (I=0.027; p=.008) ( Figure 1A ).
Consistently, +12 CLL harboring NOTCH1 mutations carried deletion 13q14 only exceptionally (0/19). Consistent with the pivotal observations, 5,7 also in +12 CLL NOTCH1 mutations distributed in a mutually exclusive fashion with deletions of 17p13 and 11q22-q23 ( Figure 1A ). were used to build a hierarchical model of genetic subgroups for OS prediction in CLL with +12. The outcome of +12 CLL with NOTCH1 mutations was poor, similar to cases with +12 and TP53 disruption or 11q22-q23 deletion and significantly worse than patients with +12 as an isolated abnormality or plus 13q14 deletion ( Figure 1C ).
NOTCH1 mutations represent therefore an independent adverse prognostic factor of OS among +12 CLL, allowing a new genetic prognostic stratification of patients with this intermediate risk marker.
Gene expression profiling of +12 CLL with NOTCH1 mutations
To understand whether NOTCH1 mutations induced a distinctive transcriptional profile in +12 CLL, we compared 7 NOTCH1 mutated vs 7 NOTCH1 wild type cases in a cohort of patients carrying +12 (Supplemental Table 1 ).
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This analysis showed that NOTCH1 mutated cases formed a tight clustering ( Figure 1D ) with 2 patients incorrectly placed. Of these, one later developed a TP53 mutation and a myelodisplastic syndrome (CLL_00248, Supplemental Table 1 ).
Sixty-five differentially expressed genes (Supplemental Table 2 ) were selected, the majority being upmodulated in NOTCH1 mutated samples. DAVID functional annotation analysis highlighted an overrepresentation of cell cycle related genes, indicating that NOTCH1 mutations induce a proliferative advantage that might explain the clinically aggressive behavior ( Figure 1D ). We also observed significantly higher levels of IgM expression in NOTCH1 mutated cases. It is known that IgM expression is higher in cells with increased ability to respond to external stimuli, 12, 13 indicating that the NOTCH1 mutated clone might survive and expand also thanks to these interactions. Intriguingly, ~30% of the upregulated transcripts were located on chromosome 12. This observation might be ascribed to the fact that +12 was present as a single alteration in all NOTCH1 mutated cases, whereas in the NOTCH1 wild-type subgroup the scenario was more complex, with 3 cases displaying only +12 and 4 cases one or more additional chromosomal aberrations.
Among the transcripts previously reported as associated with a +12 signature, we confirmed the upregulation of ANAPC5, GLIPR1, TIMELESS and SLC2A6. 14, 15 In summary, this study highlights that NOTCH1 mutations in +12 CLL: i) preferentially cluster with cases harboring +12 as sole genetic abnormality; ii) account for 24% of cases and are more frequently detected in cases with unfavorable biological markers; iii) associate with a peculiar gene expression profiling; iv) predict a poor outcome, stratifying +12 CLL in two distinct subgroups, and v) are not associated with TP53 disruption or 11q deletion, thus making them even more useful in a genetic hierarchical 
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Mutation analysis of NOTCH1
The NOTCH1 (exon 34; RefSeq NM_017617.2) mutation hotspot previously identified (Rossi et al, Blood 2011) in CLL was analyzed in blind with respect to clinical data by PCR amplification and direct sequencing of genomic DNA extracted from fresh or frozen peripheral blood mononuclear cells (PBMC) obtained at presentation. Purified amplicons were subjected to conventional DNA Sanger sequencing using the ABI PRISM 3100
Genetic Analyzer (Applied Biosystems, CA). Sequences were compared to the corresponding germline RefSeq sequences using the Mutation Surveyor Version 2.41 software package (SoftGenetics, State College, PA) after both automated and manual curation. All variants were sequenced from both strands on independent PCR products.
Synonymous mutations, reported polymorphisms and changes present in the matched normal DNA were removed from the analysis. All PCR primers and conditions are available upon request.
The presence of NOTCH1 c.7544_7545delCT alleles was also investigated by ARMS PCR approach. ARMS PCR was performed utilizing two forward (For) and one common reverse agarose gels by electrophoresis and visualized after staining with ethidium bromide. Based on a dilution curve, ARMS is capable of detecting a mutation present in at least 10% of the alleles. 
Statistical analysis
RNA extraction, microarray preparation and data analysis
Total RNA was extracted from fresh leukemia cells using the RNeasy mini procedure (Qiagen, Hilden, Germany) according to the manufacturer's instructions with minor modifications. No further purification was performed since the percentage of leukemic cells was greater than 90%.
For oligonucleotide array analysis, the HGU133 Plus 2.0 gene chips (Affymetrix, Santa Clara, CA) were used. Sample preparation and microarray processing were performed as previously described (Chiaretti S et al. Genes Chromosomes Cancer, 2011 
